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ABSTRACT
Hepatitis B virus (HBV) is one  of the public-health issues worldwide. Approximately two billion people 
are infected with HBV, and about 350 million people are chronic carriers globally. About 3% of the world 
population is infected with hepatitis C virus (HCV). Oncology patients receiving packed red blood cell 
suspensions and other blood products usually are in the high-risk group for infections due to these viruses. 
The aim of the study was to detect the seroprevalence of hepatitis B and hepatitis C among chemotherapy 
patients at the Oncology Department of the Tepecik Education and Research Hospital. HBsAg, anti-HBs, 
anti-HBcIgM, anti-HBc total and anti-HCV assays were studied by enzyme immunoassay method (Dia-
sorin, Italy) in serum samples of patients (n=448) referred to the Department of Oncology of the Tepecik 
Education and Research Hospital during 1 June  2006–1 January 2007. Of the 448 patients, 19 (4.2%) were 
HBsAg-positive, and three (0.7%) had  anti-HCV positivity. In this study, the seroprevalence of HBV was 
similar to previous data in Turkey. This could be due to widespread vaccination programmes. The sero-
prevalence of low anti-HCV may be because of controlled blood transfusion. Oncology patients should be 
monitored for their protective antibody levels against HBV, and they must be included in the vaccination 
programme. Their anti-HCV status should also be checked as well. 
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INTRODUCTION
Hepatitis B virus (HBV), a worldwide health prob-
lem, can cause serious infections and has a carriage 
rate of 20% (1). Globally, four hundred million peo-
ple are infected with HBV (http://www.who.int/
mediacentre/factsheets/fs204/en/index.html). Al-
most 50% of them have cirrhosis or hepatocellular 
carcinoma. Approximately 3-5 million are carriers 
in Turkey (2). The seropositivity of HBsAg is 3.4% 
in the Western region while it is 8% in Eastern and 
Southeast Anatolia (3). Exposure to HBV increases 
with age in both urban and rural areas. Gurol et al. 
reported that the overall seroprevalence of HBV in 
Turkey was 4.19% (4). It is estimated that 3% of 
the world population is chronically infected with 
hepatitis C virus (HCV) (5). In Western Europe, the 
prevalence of HCV ranges from 0.4% to 3%. It is 
higher in Eastern Europe and the Middle East (6). 
The seroprevalence of HCV (1.2-4%)  in Turkey is 
less than that of HBV, and this prevalence is less 
than 1% among blood donors (7).
Chemotherapy, which suppresses the immune 
system, can cause an increment in HBV DNA (vi-
ral load) and can damage the liver as the immune 
system cannot keep it  under control (http://www.
hbvadvocate.org/news/NewsUpdates_pdf/News_
Review_2011/HBJ-8.4.pdf). Besides, chemothera-
peutic medication can be directly hepatotoxic, and 
some chemotherapeutic agents and corticosteroids 
may damage the liver or may even lead to fulmi-
nant hepatitis and liver insufficiency by stimulat-Seroprevalence of hepatitis among oncology patients Kose S et al.
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ing viral replication. In HBV genome, there is a spe-
cific area responding to corticosteroids and directly 
stimulating replication (8,9). It has been reported 
that high viral load before chemotherapy, HBeAg 
positivity, steroid-use, young age, male gender, 
lymphoma, or breast cancer can be risk factors for 
reactivation of HBV infection (10,11).
The level of hepatitis C viral RNA in blood has been 
shown to increase during chemotherapy and im-
munosuppression. At the same time, for those with 
pre-existing liver dysfunction, the transaminase 
levels often normalize during immunosuppression. 
After chemotherapy or immunosuppressant treat-
ment, the hepatitis C viral RNA decreases with a 
simultaneous rise in transaminase levels (12). 
The aim of our study was to evaluate the sero-
prevalence of hepatitis B and hepatitis C among pa-
tients with malignancy due to immunsuppression 
and also to evaluate the correlation of incidence 
of hepatitis and chemotherapy application/blood 
transfusion and association between the types of 
cancers and HBsAg/anti-HCV at the Oncology De-
partment of the Tepecik Education and Research 
Hospital. 
MATERIALS AND METHODS
Patients admitted to the oncology outclinic of the 
Tepecik Education and Research Hospital, during 
1 June  2006—1 January 2007, were included  in 
the study. This study included 448  outclinic pa-
tients. Enlighted approval was taken from these pa-
tients. Serum samples were obtained to study 
HBsAg, anti-HBs, anti-HBc IgM, anti-HBc total, and 
anti-HCV assays by enzyme immunoassay method 
(EIA) (Etimax, Diasorin, Italy) at the Infectious Dis-
eases and Clinical Microbiology Laboratory of the 
Tepecik Education and Research Hospital. Statisti-
cal analysis of correlation between chemotherapy 
application/blood transfusion and the incidence of 
hepatitis and also between types of cancer and HB-
sAg/anti-HCV seroprevalence was performed using 
the SPSS software (version 13.0).                             
RESULTS
Of the 448 patients, 317 (70.8%) were women and 
131 (29.2%) were men. Their mean age was 54 
years. Types of cancer detected included breast can-
cer (57%), gastrointestinal system cancers (24.2%), 
and head-neck cancers (6.4%). Other types of can-
cers included lung, gynaecological and genitouri-
nary system, soft tissue, and skin cancers, and can-
cer with unknown primary localization. The mean 
duration of diagnosis of cases was 29.7 months. 
Chemotherapy was not administered in 5.7% of 
the cases. Blood transfusion took place in 36.5% of 
the cases. The positivity of HBsAg  was determined 
in 19 (4.2%) individuals, and the positivity of anti-
HCV was found in three (0.7%) patients. HBsAg 
was negative in 429 (95.8%) patients. Anti-HBc 
total was positive in 172 (38.4%) patients. Thirty-
one (18.1%) patients had isolated anti-HBc total 
positivity, and 155 patients (34,6%) had anti-HBs 
positivity (Table). 
Table.  Presentation of hepatitis B and C serolo- 
gical parameters of oncology patients 
(n=448)
Hepatitis marker Positive Negative 
No. % No.        %
HBsAg 19 4.2 429 95.8
Anti-HBs 155  34.6 293 65.4
Anti-HBc total 172 38.4 276 61.6
Anti-HCV 3 0.7 445 99.3
No significant correlation was found between 
chemotherapy application/blood transfusion and 
the  incidence of hepatitis. No significant associa-
tion was determined between types of cancers and 
HBsAg/anti-HCV. 
DISCUSSION
In patients receiving chemotherapy, serious prob-
lems, such as delay in treatment, decrease in dose 
concentration, and even treatment interruption or 
fulminant hepatitis have been observed due to re-
activation of hepatitis (8,9,13).
In our study, HBsAg positivity was determined as 
4.2% and anti-HCV positivity as 0.7%. Anti-HBc 
total was found to be positive in 172 patients while 
31 of these patients had isolated anti-HBc total 
positivity. In our study, 155 (34,6%) patients had 
anti-HBs positivity. 
Kebudi et al. compared the prevalence of pre- and 
post-treatment hepatitis B and C in 50 paediatric 
oncology patients who received multiple transfu-
sions and intensive chemotherapy, and they deter-
mined that children infected with HBV during im-
munosuppressive therapy are at a greater risk of   
becoming chronic carriers, and precautions must 
be taken for immunization of these children after 
treatment (14). Monteleone et al. reported the sero-
prevalence (8.9%) of hepatitis C among paediatric 
oncology patients who received blood transfusions 
(15). Demirkaya et al. investigated the trend in fre-
quency after the routine application of hepatitis B 
vaccine and to determine the frequency of hepatitis 
B and C infections (16). They found HBsAg serop-
ositivity in one of  94 lymphoma and solid tumour 
patients; none had developed hepatitis C but one 
of them got HCV during follow-up (16).Kose S et al. Seroprevalence of hepatitis among oncology patients
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Kocabas et al. reported that a higher seroprevalence 
of HBV and HCV among paediatric patients with 
cancer (17). Topeli et al. reported HBsAg positiv-
ity in 11 (13.2%) of 83 cancer patients, anti-HCV 
positivity in 10 (12.0%) patients, and both HBsAg 
and anti-HCV positivity were detected in one 
(1.2%) patient (18). Utkan et al. reported that 
oncology patients had HBsAg and anti-HCV posi-
tivity (4.8% and 2.8% respectively) (19).
Malaguernera et al. reported the seroprevalence 
of anti-HCV among 236 elderly cancer patients 
compared to 300 elderly volunteers. Of the 236 
elderly cancer patients, 87 (36%) were positive for 
HCV antibodies, and 32 (10%) of the 300 elderly 
patients were positive for hepatitis C. A compari-
son between the two groups showed the significant 
difference (p<0.001) between patients with kidney 
cancer, bladder cancer, or prostate cancer and the 
control group. These patients were more prone to 
acquire HCV infection because of their frequent 
hospitalizations, and the immunological changes 
in patients with tumours may lower their threshold 
for HCV infection (20).
Uzun et al. reported the prevalence (6.7%) of anti-
HCV positivity among lung cancer patients, which 
was significantly higher compared to the normal 
Turkish population (21).
Eren et al. reviewed the medical records of 4,400 pa-
tients undergoing cytotoxic chemotherapy at the 
Medical Oncology Department of the Selcuk Univer-
sity for the July 2004—July 2007 period (22). In to-
tal, 1,826 patients had records of hepatitis B serolo- 
gy. They found HBsAg seropositivity (about 5%), 
which is very close to the estimated seroprevalence 
of hepatitis B in Turkey. Hepatitis B reactivated in 
15% of patients who were undergoing cytotoxic 
chemotherapy (22). 
In our study, the seroprevalence of HBV was similar 
to previous data in Turkey. Anti-HCV positivity was 
found in three (0.7%) patients. The low seropreva-
lence of HBV could be due to ongoing vaccination 
programmes and screening of blood products for 
HCV and HBV. Also, the widespread vaccination 
programmes against HBV can be another reason 
for the low seroprevalence of HBV. There was no 
significant correlation between chemotherapy 
application/blood transfusion and the incidence of 
hepatitis. No significant association was observed 
between types of cancers and HBsAg/anti-HCV. 
HBsAg assay should be done in all patients before 
chemotherapy or immunosuppressive treatment. 
These patients undergo invasive procedures and 
blood product transfusions, and because of this,   
hepatitis seropositivity develops. This situation 
can be followed by a risk of reactivation and ful-
minant hepatitis  after chemotherapy. Seronegative 
patients need to receive vaccination against HBV 
(23). Screening for HBV is required before chemo-
therapy, and prophylactic antiviral therapy can re-
duce not only the incidence of HBV reactivation 
but also HBV-related morbidity and mortality. On 
the other hand, the introduction of more sensitive 
screening tests and stringent donor-selection pro-
cedures has decreased the incidence of HCV infec-
tion but there is still a risk for HCV infection; so, 
these immunosuppressed patients should also be 
monitored for HCV.                                             
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